arrow
B

Benjamin Powers

University of Kansas Cancer Center
H指数:8
被引数:1,233

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term efficacy, clinical outcomes, and safety of vimseltinib in patients with tenosynovial giant cell tumor: results from the MOTION phase 3 trial

维美替尼在腱鞘巨细胞瘤患者中的长期疗效、临床结局及安全性:MOTION III期试验结果

2026-10-190
OAAI
Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial

奥拉帕尼治疗难治性异柠檬酸脱氢酶1 (IDH1) 和IDH2-mutant胆管癌: 来自美国国家癌症研究所10129期2试验的安全性和抗肿瘤活性

CANCER
IF5.1
2025-02-070
PRE
Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial

pembrolizumab,放射治疗和手术与放射治疗和手术治疗肢体III期软组织肉瘤的安全性和有效性 (SU2C-SARC032): 一项开放标签,随机临床试验

LANCET
IF88.5
2024-11-010
PRE
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, doubleblind, placebo-controlled, phase 3 trial
LANCET
IF88.5
2024-06-013
PRE
SWOG 1609 cohort 48: anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancer

SWOG 1609队列48: 晚期胆囊癌的anti-CTLA-4和anti-PD-1

CANCER
IF5.1
2024-02-156
PRE
NCI 10129: A Phase 2 Study of the PARP inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant advanced solid tumors
2023-12-012
PRE
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

新辅助-辅助或仅辅助的Pembrolizumab治疗晚期黑色素瘤

2023-03-02327
OA